{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:09:52Z","timestamp":1792613392905,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthroplasty"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rising prevalence of obesity and type 2 diabetes mellitus (T2DM) among patients undergoing total joint arthroplasty (TJA) presents a significant clinical challenge, increasing the risk of postoperative complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potential perioperative optimization strategy, but their impact on TJA outcomes remains debated. This systematic review was conducted to synthesize the evidence on the risks and benefits of GLP-1 RA use in adult patients undergoing primary TJA\u2014specifically, total hip arthroplasty (THA), total knee arthroplasty (TKA), and total shoulder arthroplasty (TSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PubMed, Scopus, and Web of Science databases were searched from their inception to June 16, 2025, for studies comparing postoperative outcomes in adult patients undergoing primary total joint arthroplasty (TJA) and using GLP-1 RAs versus a control group. Data on study characteristics, patient demographics, and postoperative outcomes were extracted. Due to significant heterogeneity and overlap in data sources, a narrative synthesis rather than meta-analysis of the findings was conducted. Study quality was assessed using the Newcastle\u2013Ottawa Scale (NOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen retrospective cohort studies involving an aggregate total of 318,143 patients (114,365 THA, 125,505 TKA, 78,273 TSA) were included, with 56,132 receiving GLP-1 RAs. In THA and TKA, GLP-1 RAs use was associated with a reduced risk of periprosthetic joint infection (PJI) (e.g., 1.6% vs. 2.9% at 2\u00a0years for THA) and lower 90-day readmission rates (e.g., 1.1% vs. 2.0% for TKA and 1.6% vs. 2.0% for THA). When analyzed by exposure timing, the reduced PJI risk was most consistent in studies that defined GLP-1 RA use in the immediate perioperative period. Reported mean length of stay (LOS) was generally similar or slightly shorter among GLP-1 RA users compared to controls. Multiple studies reported either a reduction or no significant difference in the risk of 90-day emergency department visits. The short-term revision rates and dislocations were infrequent and did not differ significantly between groups in most of the included studies. In the TSA, evidence was inconsistent, with reduced odds of 90-day surgical site infection (SSI) (OR 0.25) in one study; however, no clear trend was observed. Gastrointestinal side effects and conflicting systemic risks were noted across procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current observational data suggest that perioperative GLP-1 RA use in patients undergoing total hip or knee arthroplasty is not associated with a consistent increase in short-term revision rates and may be associated with a reduced risk of postoperative infection. Evidence regarding TSA remains inconclusive. However, given the retrospective nature of the evidence, substantial overlap in data sources, heterogeneity in exposure definitions, and short-term follow-up, these findings should be considered hypothesis-generating. Future prospective, randomized controlled trials with standardized exposure definitions and longer follow-up are required to confirm these associations and establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42836-026-00375-w","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:13:16Z","timestamp":1774253596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know"],"prefix":"10.1186","volume":"8","author":[{"given":"Omar","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad G.","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Abdo","family":"Khalafallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla M.","family":"Hadhoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Elmenawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"17","key":"375_CR1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2106\/JBJS.17.01617","volume":"100","author":"M Sloan","year":"2018","unstructured":"Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the US, 2014 to 2030. JBJS. 2018;100(17):1455\u201360.","journal-title":"JBJS"},{"issue":"4","key":"375_CR2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2106\/00004623-200704000-00012","volume":"89","author":"S Kurtz","year":"2007","unstructured":"Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. JBJS. 2007;89(4):780\u20135.","journal-title":"JBJS"},{"key":"375_CR3","doi-asserted-by":"crossref","unstructured":"Bourne R, Mukhi S, Zhu N, Keresteci M, Marin M. Role of obesity on the risk for total hip or knee arthroplasty. Clinical Orthopaedics and Related Research\u00ae. 2007 Dec 1;465:185\u20138.","DOI":"10.1097\/BLO.0b013e3181576035"},{"key":"375_CR4","unstructured":"Springer B, Parvizi JA, Austin M, Backe H, Della Valle C, Kolessar D, Kreuzer S, Malinzak R, Masri B, McGrory B, Mochel D. Obesity and total joint arthroplasty a literature based review. Journal of Arthroplasty. 2013;28(5)."},{"issue":"20","key":"375_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arth.2005.04.023","volume":"1","author":"RS Namba","year":"2005","unstructured":"Namba RS, Paxton L, Fithian DC, Stone ML. Obesity and perioperative morbidity in total hip and total knee arthroplasty patients. J Arthroplasty. 2005;1(20):46\u201350.","journal-title":"J Arthroplasty"},{"issue":"7","key":"375_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.arth.2014.02.021","volume":"29","author":"MC Inacio","year":"2014","unstructured":"Inacio MC, Paxton EW, Fisher D, Li RA, Barber TC, Singh JA. Bariatric surgery prior to total joint arthroplasty may not provide dramatic improvements in post-arthroplasty surgical outcomes. J Arthroplasty. 2014;29(7):1359\u201364.","journal-title":"J Arthroplasty"},{"issue":"8","key":"375_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1054\/arth.2000.9054","volume":"15","author":"J Parvizi","year":"2000","unstructured":"Parvizi J, Trousdale RT, Sarr MG. Total joint arthroplasty in patients surgically treated for morbid obesity. J Arthroplasty. 2000;15(8):1003\u20138.","journal-title":"J Arthroplasty"},{"issue":"3","key":"375_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153\u201365.","journal-title":"Cell Metab"},{"key":"375_CR9","first-page":"372","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:372.","journal-title":"BMJ"},{"key":"375_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2008","unstructured":"Higgins JP. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration and John Wiley & Sons Ltd; 2008."},{"key":"375_CR11","unstructured":"Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011;2(1):1\u20132."},{"issue":"4","key":"375_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2106\/JBJS.24.00468","volume":"107","author":"BI Kim","year":"2025","unstructured":"Kim BI, LaValva SM, Parks ML, Sculco PK, Della Valle AG, Lee GC. Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA. JBJS. 2025;107(4):348\u201355.","journal-title":"JBJS"},{"issue":"11","key":"375_CR13","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-24-00148","volume":"8","author":"RJ Magaldi","year":"2024","unstructured":"Magaldi RJ, Strecker SE, Witmer D. Glucagon-like peptide-1 agonists in total hip arthroplasty: Complications, readmissions, and patient-reported outcomes. JAAOS Global Research & Reviews. 2024;8(11):e24.","journal-title":"JAAOS Global Research & Reviews"},{"issue":"1","key":"375_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jorep.2024.100501","volume":"4","author":"R Baum","year":"2025","unstructured":"Baum R, La Poche A, Choudhury N, Saha P, Naziri Q, Zikria BA. Short-term complications in elective joint reconstruction: A retrospective assessment of the impact of GLP-1 agonists. Journal of Orthopaedic Reports. 2025;4(1):100501.","journal-title":"Journal of Orthopaedic Reports"},{"issue":"4","key":"375_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jse.2024.07.045","volume":"34","author":"Z Elsabbagh","year":"2025","unstructured":"Elsabbagh Z, Haft M, Murali S, Best M, McFarland EG, Srikumaran U. Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty? J Shoulder Elbow Surg. 2025;34(4):997\u20131006.","journal-title":"J Shoulder Elbow Surg"},{"issue":"3","key":"375_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","volume":"39","author":"ML Magruder","year":"2024","unstructured":"Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA. Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. J Arthroplasty. 2024;39(3):716\u201320.","journal-title":"J Arthroplasty"},{"issue":"30","key":"375_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2024.101506","volume":"1","author":"KY Heo","year":"2024","unstructured":"Heo KY, Goel RK, Fuqua A, Holmes JS, Muffly BT, Erens GA, et al. Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total knee arthroplasty in patients with type-2 diabetes. Arthroplasty Today. 2024;1(30):101506.","journal-title":"Arthroplasty Today"},{"key":"375_CR18","doi-asserted-by":"crossref","unstructured":"Kim BI, Khilnani TK, LaValva SM, Goodman SM, Della Valle AG, Lee GC. Utilization of Glucagon-Like Peptide-1 Receptor Agonist at the Time of Total Hip Arthroplasty for Patients Who Have Morbid Obesity. The Journal of Arthroplasty. 2024.","DOI":"10.1016\/j.arth.2024.12.008"},{"key":"375_CR19","doi-asserted-by":"crossref","unstructured":"Katzman JL, Haider MA, Cardillo C, Rozell JC, Schwarzkopf R, Lajam CM. Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective. The Journal of Arthroplasty. 2025.","DOI":"10.1016\/j.arth.2025.02.042"},{"key":"375_CR20","doi-asserted-by":"crossref","unstructured":"Choudhury A, Van Boxtel M, Hanley J. The impact of GLP-1 receptor agonists on postoperative outcomes following total shoulder arthroplasty. InSeminars in Arthroplasty: JSES 2025. 35 (1);94\u201399. WB Saunders.","DOI":"10.1053\/j.sart.2024.10.001"},{"key":"375_CR21","first-page":"10","volume":"13","author":"MF Levidy","year":"2022","unstructured":"Levidy MF, Vatsia S, Gohel N, Rowe N, Kirchner GJ, Demedal S, et al. The Effects of Glucagon-Like Peptide-1 Agonist Therapy on Risk of Infection, Fracture, and Early Revision in Primary Total Joint Arthroplasty. JAAOS-Journal of the American Academy of Orthopaedic Surgeons. 2022;13:10\u20135435.","journal-title":"JAAOS-Journal of the American Academy of Orthopaedic Surgeons"},{"issue":"12","key":"375_CR22","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1016\/j.arth.2024.05.079","volume":"39","author":"A Buddhiraju","year":"2024","unstructured":"Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024;39(12):2911\u20135.","journal-title":"J Arthroplasty"},{"issue":"5","key":"375_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jse.2024.09.012","volume":"34","author":"JJ Lawand","year":"2025","unstructured":"Lawand JJ, Tansey PJ, Ghali A, Tye C, Hantouly A, Fares MY, et al. Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty. J Shoulder Elbow Surg. 2025;34(5):1152\u20137.","journal-title":"J Shoulder Elbow Surg"},{"issue":"11","key":"375_CR24","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.arth.2023.05.071","volume":"38","author":"ML Magruder","year":"2023","unstructured":"Magruder ML, Yao VJ, Rodriguez AN, Ng MK, Sasson V, Erez O. Does semaglutide use decrease complications and costs following total knee arthroplasty? J Arthroplasty. 2023;38(11):2311\u20135.","journal-title":"J Arthroplasty"},{"key":"375_CR25","doi-asserted-by":"crossref","unstructured":"Verhey JT, Austin RP, Tarabichi S, Paul B, Deckey DG, Christopher ZK, Spangehl MJ, Bingham JS. GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?. The Journal of Arthroplasty. 2025 Mar 11.","DOI":"10.1016\/j.arth.2025.03.012"},{"issue":"3","key":"375_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jseint.2024.10.006","volume":"9","author":"AE Seddio","year":"2025","unstructured":"Seddio AE, Wilhelm CV, Gouzoulis MJ, Islam W, Vasudevan RS, Halperin SJ, et al. Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: A promising new addition to preoperative optimization. JSES international. 2025;9(3):735\u201340.","journal-title":"JSES international"},{"issue":"1","key":"375_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000321","volume":"14","author":"A Shankar","year":"2025","unstructured":"Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: Implications for invasive cardiac interventions and surgery. Cardiovascular Endocrinology & Metabolism. 2025;14(1):e00321.","journal-title":"Cardiovascular Endocrinology & Metabolism"},{"issue":"12","key":"375_CR28","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/oby.24177","volume":"32","author":"NU Paddu","year":"2024","unstructured":"Paddu NU, Lawrence B, Wong S, Poon SJ, Srivastava G. Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study. Obesity. 2024;32(12):2255\u201363.","journal-title":"Obesity"},{"issue":"1","key":"375_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/SLA.0b013e31827b6bbc","volume":"257","author":"S Kwon","year":"2013","unstructured":"Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg. 2013;257(1):8\u201314.","journal-title":"Ann Surg"},{"key":"375_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"375_CR31","doi-asserted-by":"crossref","unstructured":"Lee S, Singh K, Clark SC, Goh GS. The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients. The Journal of arthroplasty. 2025 Oct 8.","DOI":"10.1016\/j.arth.2025.09.054"},{"issue":"164","key":"375_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"1","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;1(164):156113.","journal-title":"Metabolism"},{"key":"375_CR33","first-page":"1","volume":"22","author":"Y Tan","year":"2025","unstructured":"Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2025;22:1\u20138.","journal-title":"Acta Diabetol"},{"issue":"1","key":"375_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3361309","volume":"2021","author":"TT Cai","year":"2021","unstructured":"Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Biomed Res Int. 2021;2021(1):3361309.","journal-title":"Biomed Res Int"},{"key":"375_CR35","doi-asserted-by":"crossref","unstructured":"Ushakumari DS, Sladen RN. ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists. Anesthesiology. 2023 Nov 20.","DOI":"10.1097\/ALN.0000000000004776"},{"key":"375_CR36","unstructured":"Douketis JD, Lip G. Perioperative management of patients receiving anticoagulants. UpToDate. 2019:1\u201328."},{"issue":"14","key":"375_CR37","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.3390\/ijms26146777","volume":"26","author":"M Kr\u00f3l","year":"2025","unstructured":"Kr\u00f3l M, Kupnicka P, \u017bychowska J, Kapczuk P, Szu\u0107ko-Kociuba I, Prajwos E, et al. Molecular insights into the potential cardiometabolic effects of GLP-1 receptor analogs and DPP-4 inhibitors. Int J Mol Sci. 2025;26(14):6777.","journal-title":"Int J Mol Sci"},{"key":"375_CR38","doi-asserted-by":"crossref","unstructured":"Chen TH, Hu EH, Chen DY, Lin Y, Chou TS, Lin MS, Yang NI, Wang CY, Hung MJ, Tsai ML. GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes. JAMA Network Open. 2025 Sep 2;8(9):e2530952-.","DOI":"10.1001\/jamanetworkopen.2025.30952"}],"container-title":["Arthroplasty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42836-026-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42836-026-00375-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42836-026-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:02:40Z","timestamp":1774299760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42836-026-00375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1186\/s42836-026-00375-w","relation":{},"ISSN":["2524-7948"],"issn-type":[{"value":"2524-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}